Platelet aggregation inhibition as adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA).
Contraindication: What are the special precautions to be followed?
Under following conditions, use of this medication is inadvisable. Its use should be withhold as it would cause harm to the patient Active internal bleeding (within 6 weeks), GI or GE bleeding of clinical significance, history of cerebrovascular accident (CVA) within 2 years or CVA with a significant neurological deficit, bleeding diathesis, administration of oral anticoagulant within 7 days unless prothrombin time is <1.2 times control, thrombocytopenia, recent major surgery or trauma, intracranial neoplasm, severe uncontrolled hypertension, presumed or documented history of vaculitis.
Other Precaution to be observed while taking this medication
Free plasma concentration of the drug decreases rapidly with an initial half life of
What are possible side effects of this medication ?
Constipation, ileus, bleeding, thrombocytopenia, atrial fibrillation/flutter, complete AV block, palpitation, SVT, abnormal thinking, dizziness human antichimeric antibody development.